Furthermore, combination therapy with IFN and a nuclear export inhibitor (e.g., KPT-330) has been shown to inhibit tumorigenesis and progression in CRC by inducing ZBP1-dependent PANoptosis through modulation of the regulatory relationship between ADAR1 and ZBP1 [83]. The gene discussed is ZBP1; the disease is colorectal carcinoma.